Literature DB >> 17804797

The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain.

Eric N Hampton1, Mark W Knuth, Jun Li, Jennifer L Harris, Scott A Lesley, Glen Spraggon.   

Abstract

Mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9) are strongly associated with levels of low-density lipoprotein cholesterol in the blood plasma and, thereby, occurrence or resistance to atherosclerosis and coronary heart disease. Despite this importance, relatively little is known about the biology of PCSK9. Here, the crystal structure of a full-length construct of PCSK9 solved to 1.9-A resolution is presented. The structure contains a fully folded C-terminal cysteine-rich domain (CRD), showing a distinct structural similarity to the resistin homotrimer, a small cytokine associated with obesity and diabetes. This structural relationship between the CRD of PCSK9 and the resistin family is not observed in primary sequence comparisons and strongly suggests a distant evolutionary link between the two molecules. This three-dimensional homology provides insight into the function of PCSK9 at the molecular level and will help to dissect the link between PCSK9 and CHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804797      PMCID: PMC1976225          DOI: 10.1073/pnas.0703402104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

Authors:  Jamie Cameron; Øystein L Holla; Trine Ranheim; Mari Ann Kulseth; Knut Erik Berge; Trond P Leren
Journal:  Hum Mol Genet       Date:  2006-03-28       Impact factor: 6.150

2.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

3.  Mechanism of amelioration of insulin resistance by beta3-adrenoceptor agonist AJ-9677 in the KK-Ay/Ta diabetic obese mouse model.

Authors:  H Kato; M Ohue; K Kato; A Nomura; K Toyosawa; Y Furutani; S Kimura; T Kadowaki
Journal:  Diabetes       Date:  2001-01       Impact factor: 9.461

4.  Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

Authors:  Thomas A Lagace; David E Curtis; Rita Garuti; Markey C McNutt; Sahng Wook Park; Heidi B Prather; Norma N Anderson; Y K Ho; Robert E Hammer; Jay D Horton
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

5.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

6.  Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

Authors:  Sahng Wook Park; Young-Ah Moon; Jay D Horton
Journal:  J Biol Chem       Date:  2004-09-22       Impact factor: 5.157

7.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

8.  Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.

Authors:  Timothy S Fisher; Paola Lo Surdo; Shilpa Pandit; Marco Mattu; Joseph C Santoro; Doug Wisniewski; Richard T Cummings; Alessandra Calzetta; Rose M Cubbon; Paul A Fischer; Anil Tarachandani; Raffaele De Francesco; Samuel D Wright; Carl P Sparrow; Andrea Carfi; Ayesha Sitlani
Journal:  J Biol Chem       Date:  2007-05-10       Impact factor: 5.157

9.  The crystal structure of an autoprocessed Ser221Cys-subtilisin E-propeptide complex at 2.0 A resolution.

Authors:  S C Jain; U Shinde; Y Li; M Inouye; H M Berman
Journal:  J Mol Biol       Date:  1998-11-20       Impact factor: 5.469

10.  The crystal structure of the proprotein processing proteinase furin explains its stringent specificity.

Authors:  Stefan Henrich; Angus Cameron; Gleb P Bourenkov; Reiner Kiefersauer; Robert Huber; Iris Lindberg; Wolfram Bode; Manuel E Than
Journal:  Nat Struct Biol       Date:  2003-07
View more
  45 in total

1.  PCSK9 function and physiology.

Authors:  Andrew S Peterson; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2008-07       Impact factor: 5.922

2.  Beyond anti-PCSK9 therapies: the potential role of resistin inhibitors.

Authors:  Amirhossein Sahebkar
Journal:  Nat Rev Cardiol       Date:  2013-11-12       Impact factor: 32.419

3.  PCSK9 function and physiology.

Authors:  Andrew S Peterson; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2008-03-28       Impact factor: 5.922

4.  Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.

Authors:  S Li; R X Xu; Y Zhang; Y L Guo; C G Zhu; G Liu; Q Dong; J J Li
Journal:  J Endocrinol Invest       Date:  2015-05-24       Impact factor: 4.256

5.  Peeking into a cool future: genome editing to delete PCSK9 and control hypercholesterolemia in a single shot.

Authors:  Sergio Fazio; Hagai Tavori
Journal:  Circ Res       Date:  2014-08-15       Impact factor: 17.367

6.  Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists.

Authors:  Yingnan Zhang; Mark Ultsch; Nicholas J Skelton; Daniel J Burdick; Maureen H Beresini; Wei Li; Monica Kong-Beltran; Andrew Peterson; John Quinn; Cecilia Chiu; Yan Wu; Steven Shia; Paul Moran; Paola Di Lello; Charles Eigenbrot; Daniel Kirchhofer
Journal:  Nat Struct Mol Biol       Date:  2017-08-21       Impact factor: 15.369

Review 7.  PCSK9: From Basic Science Discoveries to Clinical Trials.

Authors:  Michael D Shapiro; Hagai Tavori; Sergio Fazio
Journal:  Circ Res       Date:  2018-05-11       Impact factor: 17.367

8.  Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.

Authors:  John S Chorba; Adri M Galvan; Kevan M Shokat
Journal:  J Biol Chem       Date:  2017-12-19       Impact factor: 5.157

9.  Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.

Authors:  Adri M Galvan; John S Chorba
Journal:  J Lipid Res       Date:  2018-11-21       Impact factor: 5.922

10.  Structure and protective efficacy of the Staphylococcus aureus autocleaving protease EpiP.

Authors:  Misty L Kuhn; Prachi Prachi; George Minasov; Ludmilla Shuvalova; Jiapeng Ruan; Ievgeniia Dubrovska; James Winsor; Monica Giraldi; Massimiliano Biagini; Sabrina Liberatori; Silvana Savino; Fabio Bagnoli; Wayne F Anderson; Guido Grandi
Journal:  FASEB J       Date:  2014-01-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.